Document Detail


Pilot study on the plasma pharmacokinetics of fumonisin B1 in cows following a single dose by oral gavage or intravenous administration.
MedLine Citation:
PMID:  8581325     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The pharmacokinetic fate of the mycotoxin fumonisin B1 (FB1) was investigated using 4 Holstein cows. Two animals each were administered FB1 intravenously (0.05 or 0.20 mg kg-1) and by oral gavage (1.0 or 5.0 mg kg-1). Blood samples were collected at specific time intervals over 12 hr postdosing, then daily for 13 more days, and analyzed for FB1, the hydroxylated aminopental metabolite, and their conjugates. Following intravenous dosing, the plasma-concentration profile of FB1 underwent a very rapid biexponential decrease, with toxin concentrations falling below detectable levels by 120 min postdosing. No known metabolites were detected in plasma. The similarity in pharmacokinetic parameters between the low- and high-dose animals suggests that FB1 distribution and elimination from blood was not dose-dependent at these levels of toxin administration. Following oral administration of the toxin, no FB1 or known metabolites could be found in the plasma, indicating no or very limited bioavailability in ruminants. The effects of FB1 on plasma-free sphinganine (Sa) and free sphingosine (So) concentrations were also determined. Following oral gavage at either dose, no effects on plasma sphingolipid concentration or Sa/So ratio were noted beyond typical daily variations. At the low intravenous dose (0.05 mg kg-1), changes in Sa or So concentrations were also not apparent. However, following intravenous administration at the higher dose (0.20 mg kg-1), the plasma Sa/So ratio was increased marginally in the one dosed cow, due essentially to a transient increase in Sa concentrations, which rose by approximately 60-65% over average predose levels; So levels remained relatively constant.
Authors:
D B Prelusky; M E Savard; H L Trenholm
Related Documents :
14681345 - Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by ac...
7336975 - Antacids and sotalol absorption.
11502525 - Pharmacokinetics of clinafloxacin after single and multiple doses.
7882455 - The bioavailability and dose dependency of the deuterated anti-tumour agent 4,6-benzyli...
14681345 - Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by ac...
8369955 - Chronic corticosterone administration enhances behavioral sensitization to amphetamine ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Natural toxins     Volume:  3     ISSN:  1056-9014     ISO Abbreviation:  Nat. Toxins     Publication Date:  1995  
Date Detail:
Created Date:  1996-03-19     Completed Date:  1996-03-19     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9212382     Medline TA:  Nat Toxins     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  389-94     Citation Subset:  IM    
Affiliation:
Centre for Food and Animal Research, Central Experimental Farm, Agriculture and Agri-Food Canada, Ottawa, Ontario, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Absorption
Administration, Oral
Animals
Biological Availability
Carcinogens, Environmental / administration & dosage,  pharmacokinetics*
Cattle
Dose-Response Relationship, Drug
Enzyme Inhibitors / blood
Female
Fumonisins*
Injections, Intravenous
Mycotoxins / administration & dosage,  pharmacokinetics*
Pilot Projects
Sphingosine / analogs & derivatives,  blood
Chemical
Reg. No./Substance:
0/Carcinogens, Environmental; 0/Enzyme Inhibitors; 0/Fumonisins; 0/Mycotoxins; 116355-83-0/fumonisin B1; 123-78-4/Sphingosine; 764-22-7/safingol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Phytotoxic effect of deoxynivalenol and gibberella ear rot resistance of corn.
Next Document:  Effects of intravenous fumonisin B1 in rabbits: nephrotoxicity and sphingolipid alterations.